A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Medical Oncology and Therapeutics Research Bookmark and Share

Department of Medical Oncology and Therapeutics Research

City of Hope’s Department of Medical Oncology and Therapeutics Research is comprised of a multidisciplinary team of physicians, nurse practitioners, scientists and other health professionals. Together, they are dedicated to the diagnosis, treatment and research of solid tumors in adult patients to ensure optimal outcomes across a broad spectrum of diagnoses.
 
The department has dedicated faculty for both its inpatient service and outpatient clinics, which are organized around cancer types. The staff also works closely with City of Hope’s surgery, radiation oncology and supportive care medicine departments to provide coordinated, comprehensive cancer care to patients and caregivers.
 
Additionally, the department collaborates with the Developmental Cancer Therapeutics Program and other cancer centers to develop the next generation of cancer therapies that are more effective against the disease and less toxic to the patient. Many of these therapies are being studied in clinical trials, which are open to City of Hope patients who meet the study’s criteria.
 
“The motto of the City of Hope is ‘We Live to Cure Cancer.’ In the Department of Medical Oncology and Therapeutics Research, it's our job to implement that motto, and we mean business. 
 
The department has some of the finest and most skilled medical oncologists anywhere: Many are cited as ‘America’s Top Doctors’ and are recognized in numerous other publications as well. And all are dedicated to one interest only—YOUR INTEREST. 
 
Here at the City of Hope, you will find doctors who are highly specialized experts in their areas. More importantly, our staff have excellent communication skills and that crucial quality—empathy. Combined with our extensive portfolio of clinical trials and continual medical progress, this means our patients will get the most advanced and compassionate care available, which gives them the best opportunity to lead longer and more fulfilling lives.”
 
- Cy A. Stein, M.D., Ph.D.
Professor, Medical Oncology

Medical Oncology Clinical Trials

The Department of Medical Oncology and Therapeutics Research conducts and participates in numerous clinical trials with promising therapies that are not yet widely available. City of Hope patients who meet the trials’ criteria will have opportunities to enroll in these studies, giving them access to the novel cancer treatments that may become tomorrow’s standard of care.
 
Our searchable clinical trials database contains more information about individual trials, including study details, its eligibility criteria and its principal investigator at City of Hope.
 
The types of trials include:
  • Phase 0 trials: the earliest in-human trials studying how the new drug works and how it is absorbed and processed by the body.
  • Phase I trials: small studies whose primary goal is to ensure that the new drug is well-tolerated and to establish the maximum safe dose for patients.
  • Phase II trials: studies that examine the new drug’s effectiveness against the cancer and further evaluates it for safety.
  • Phase III trials: multi-site studies involving numerous patients that compare the new drug against current standard therapy to see if it improves survival and/or quality of life.
  • Phase IV trials: these studies are typically conducted after the new drug has been approved and monitor for its long-term safety and efficacy.
 
For information about enrolling in a clinical trial, contact our New Patient Services department at 800-826-HOPE (4673).

Professional Education Opportunities

The Department of Medical Oncology and Therapeutics Research offer multiple education opportunities for health and science professionals.
 
Medical Oncology and Hematology Fellowship: The Department of Medical Oncology and Therapeutics Research and the Department of Hematology and Hematopoietic Cell Transplantation provide a three-year fellowship training program in Medical Oncology and Hematology subspecialties for over 25 years. This fellowship is accredited by the national Accreditation Council for Graduate Medical Education (ACGME).
 
Clinical Oncology Career Development (K-12) Training: The National Cancer Institute-supported K-12 Training Program is geared for oncologists at the assistant professor level. It is intended to provide selected trainees a research career development experience by engaging them in all phases of designing, developing, implementing and evaluating cancer clinical trials. Novel investigator-initiated clinical trials are developed from trainees' basic research projects.
 
Cancer Genetics Career Development Program: The Division of Clinical Cancer Genetics offers an National Institutes of Health-funded program that provides comprehensive interdisciplinary training to highly qualified physicians and doctoral level nurses who want to become program leaders in cancer genetics, cancer prevention and control research. This program includes training in the genetics of cancer, cancer risk assessment, counseling and risk management, clinical cancer control and epidemiological research.

Research

Just as today’s cancer treatments would not be possible without prior breakthroughs, tomorrow’s therapies are reliant upon current studies and clinical trials. The Department of Medical Oncology and Therapeutics Research is instrumental in this scientific effort to develop cancer drugs that can give patients the best possible chance to survive and thrive after their diagnoses.
 
Working closely with City of Hope’s Developmental Cancer Therapeutics Program and other cancer centers, the multidisciplinary program includes basic, translational and clinical research and fosters collaborations among scientists and clinicians. The goal of this synergistic effort is to spark novel ideas that turn into new laboratory discoveries, which are then transformed into promising therapies for cancer patients with few (or no) other treatment options.
 
Highlights of Current Efforts
  • A major obstacle to successful drug treatment of brain tumors, particularly high-grade gliomas, is the blood-brain barrier, which prevents most anticancer agents from entering the central nervous system. Gliomas are also diffuse and highly infiltrative, which means no clear border exists between tumor and normal brain. Human neural stem cells hold great promise for glioma therapy due to their inherent ability to hone in on tumor cells and bypass the blood-brain barrier. This makes neural stem cells effective vehicles for drug delivery, allowing for a concentrated amount of active drug to be applied directly to tumor cells while minimizing toxicity to normal brain tissue. City of Hope is currently conducting clinical trials testing this novel approach.
Principal investigator: Jana Portnow, M.D.
 
  • Laboratory studies revealed that the mushroom extract, particularly from the common white button mushroom, contain phytochemicals that can inhibit cancer through several means. As a result of this research, City of Hope have conducted clinical trials studying mushrooms’ potential against breast cancer and prostate cancer.
Principal investigators: Melanie Palomares, M.D., M.S. and Przemyslaw Twardowski, M.D.
 
  • Liposarcoma—or cancer of the fat cells—is the second most common soft-tissue sarcoma. Protease inhibitors (currently used to treat HIV infections) may hold promise in treating this disease due to the drug’s effect on fat cells. Based on preclinical studies supporting the use of protease inhibitors on liposarcomas, City of Hope is currently conducting a clinical trial using nelfinavir against recurrent liposarcomas.
Principal investigator: Warren Chow, M.D.
 
  • The Cancer and Aging Research Program, which conducts studies to establish the best pattern of care for cancer patients aged 65 and older, including:
    • Developing an assessment tool that improves oncologists ability to anticipate chemotherapy toxicity
    • Examining how cancer drugs affect older patients differently, including how they are absorbed and processed, in addition to their associated side effects.
    • Predicting overall outcomes and developing interventions to improve outcomes among older patients.
Principal investigator: Arti Hurria, M.D.
 
  • The California Cancer Consortium program, a National Cancer Institute-funded collaboration combining the expertise of City of Hope, University of Southern California and University of California, Davis. Together, researchers and clinicians in this program are investigating:
    • Agents that can target cancer and disrupt its life and division cycles
    • Special populations who react differently to cancer drugs due to factors such as genetics, cancer subtype or abnormal organ function.
    • The biological mechanisms behind drug response and resistance.
Principal investigators: Edward Newman, Ph.D., and Robert Morgan, M.D.
 

Medical Oncology

Support this program

It takes the help of a lot of caring people to make hope a reality for our patients.  City of Hope was founded by individuals’ philanthropic efforts 100 years ago. Their efforts - and those of our supporters today - have built the foundation for the care we provide and the research we conduct. It enables City of Hope to strive for new breakthroughs and better therapies, ultimately helping more people enjoy longer, better lives.

For more information on supporting this specific program, please contact our Philanthropy Department at 800-667-5310 or philanthropy@coh.org. Or, to make a gift that supports all the research at City of Hope, donate online now.

 
We thank you for your support.
 
 
 

Medical Oncology and Therapeutics Research

Department of Medical Oncology and Therapeutics Research

City of Hope’s Department of Medical Oncology and Therapeutics Research is comprised of a multidisciplinary team of physicians, nurse practitioners, scientists and other health professionals. Together, they are dedicated to the diagnosis, treatment and research of solid tumors in adult patients to ensure optimal outcomes across a broad spectrum of diagnoses.
 
The department has dedicated faculty for both its inpatient service and outpatient clinics, which are organized around cancer types. The staff also works closely with City of Hope’s surgery, radiation oncology and supportive care medicine departments to provide coordinated, comprehensive cancer care to patients and caregivers.
 
Additionally, the department collaborates with the Developmental Cancer Therapeutics Program and other cancer centers to develop the next generation of cancer therapies that are more effective against the disease and less toxic to the patient. Many of these therapies are being studied in clinical trials, which are open to City of Hope patients who meet the study’s criteria.
 
“The motto of the City of Hope is ‘We Live to Cure Cancer.’ In the Department of Medical Oncology and Therapeutics Research, it's our job to implement that motto, and we mean business. 
 
The department has some of the finest and most skilled medical oncologists anywhere: Many are cited as ‘America’s Top Doctors’ and are recognized in numerous other publications as well. And all are dedicated to one interest only—YOUR INTEREST. 
 
Here at the City of Hope, you will find doctors who are highly specialized experts in their areas. More importantly, our staff have excellent communication skills and that crucial quality—empathy. Combined with our extensive portfolio of clinical trials and continual medical progress, this means our patients will get the most advanced and compassionate care available, which gives them the best opportunity to lead longer and more fulfilling lives.”
 
- Cy A. Stein, M.D., Ph.D.
Professor, Medical Oncology

Clinical Trials

Medical Oncology Clinical Trials

The Department of Medical Oncology and Therapeutics Research conducts and participates in numerous clinical trials with promising therapies that are not yet widely available. City of Hope patients who meet the trials’ criteria will have opportunities to enroll in these studies, giving them access to the novel cancer treatments that may become tomorrow’s standard of care.
 
Our searchable clinical trials database contains more information about individual trials, including study details, its eligibility criteria and its principal investigator at City of Hope.
 
The types of trials include:
  • Phase 0 trials: the earliest in-human trials studying how the new drug works and how it is absorbed and processed by the body.
  • Phase I trials: small studies whose primary goal is to ensure that the new drug is well-tolerated and to establish the maximum safe dose for patients.
  • Phase II trials: studies that examine the new drug’s effectiveness against the cancer and further evaluates it for safety.
  • Phase III trials: multi-site studies involving numerous patients that compare the new drug against current standard therapy to see if it improves survival and/or quality of life.
  • Phase IV trials: these studies are typically conducted after the new drug has been approved and monitor for its long-term safety and efficacy.
 
For information about enrolling in a clinical trial, contact our New Patient Services department at 800-826-HOPE (4673).

Professional Education Opportunities

Professional Education Opportunities

The Department of Medical Oncology and Therapeutics Research offer multiple education opportunities for health and science professionals.
 
Medical Oncology and Hematology Fellowship: The Department of Medical Oncology and Therapeutics Research and the Department of Hematology and Hematopoietic Cell Transplantation provide a three-year fellowship training program in Medical Oncology and Hematology subspecialties for over 25 years. This fellowship is accredited by the national Accreditation Council for Graduate Medical Education (ACGME).
 
Clinical Oncology Career Development (K-12) Training: The National Cancer Institute-supported K-12 Training Program is geared for oncologists at the assistant professor level. It is intended to provide selected trainees a research career development experience by engaging them in all phases of designing, developing, implementing and evaluating cancer clinical trials. Novel investigator-initiated clinical trials are developed from trainees' basic research projects.
 
Cancer Genetics Career Development Program: The Division of Clinical Cancer Genetics offers an National Institutes of Health-funded program that provides comprehensive interdisciplinary training to highly qualified physicians and doctoral level nurses who want to become program leaders in cancer genetics, cancer prevention and control research. This program includes training in the genetics of cancer, cancer risk assessment, counseling and risk management, clinical cancer control and epidemiological research.

Research

Research

Just as today’s cancer treatments would not be possible without prior breakthroughs, tomorrow’s therapies are reliant upon current studies and clinical trials. The Department of Medical Oncology and Therapeutics Research is instrumental in this scientific effort to develop cancer drugs that can give patients the best possible chance to survive and thrive after their diagnoses.
 
Working closely with City of Hope’s Developmental Cancer Therapeutics Program and other cancer centers, the multidisciplinary program includes basic, translational and clinical research and fosters collaborations among scientists and clinicians. The goal of this synergistic effort is to spark novel ideas that turn into new laboratory discoveries, which are then transformed into promising therapies for cancer patients with few (or no) other treatment options.
 
Highlights of Current Efforts
  • A major obstacle to successful drug treatment of brain tumors, particularly high-grade gliomas, is the blood-brain barrier, which prevents most anticancer agents from entering the central nervous system. Gliomas are also diffuse and highly infiltrative, which means no clear border exists between tumor and normal brain. Human neural stem cells hold great promise for glioma therapy due to their inherent ability to hone in on tumor cells and bypass the blood-brain barrier. This makes neural stem cells effective vehicles for drug delivery, allowing for a concentrated amount of active drug to be applied directly to tumor cells while minimizing toxicity to normal brain tissue. City of Hope is currently conducting clinical trials testing this novel approach.
Principal investigator: Jana Portnow, M.D.
 
  • Laboratory studies revealed that the mushroom extract, particularly from the common white button mushroom, contain phytochemicals that can inhibit cancer through several means. As a result of this research, City of Hope have conducted clinical trials studying mushrooms’ potential against breast cancer and prostate cancer.
Principal investigators: Melanie Palomares, M.D., M.S. and Przemyslaw Twardowski, M.D.
 
  • Liposarcoma—or cancer of the fat cells—is the second most common soft-tissue sarcoma. Protease inhibitors (currently used to treat HIV infections) may hold promise in treating this disease due to the drug’s effect on fat cells. Based on preclinical studies supporting the use of protease inhibitors on liposarcomas, City of Hope is currently conducting a clinical trial using nelfinavir against recurrent liposarcomas.
Principal investigator: Warren Chow, M.D.
 
  • The Cancer and Aging Research Program, which conducts studies to establish the best pattern of care for cancer patients aged 65 and older, including:
    • Developing an assessment tool that improves oncologists ability to anticipate chemotherapy toxicity
    • Examining how cancer drugs affect older patients differently, including how they are absorbed and processed, in addition to their associated side effects.
    • Predicting overall outcomes and developing interventions to improve outcomes among older patients.
Principal investigator: Arti Hurria, M.D.
 
  • The California Cancer Consortium program, a National Cancer Institute-funded collaboration combining the expertise of City of Hope, University of Southern California and University of California, Davis. Together, researchers and clinicians in this program are investigating:
    • Agents that can target cancer and disrupt its life and division cycles
    • Special populations who react differently to cancer drugs due to factors such as genetics, cancer subtype or abnormal organ function.
    • The biological mechanisms behind drug response and resistance.
Principal investigators: Edward Newman, Ph.D., and Robert Morgan, M.D.
 

Medical Oncology Team

Medical Oncology

Support the Medical Oncology Program

Support this program

It takes the help of a lot of caring people to make hope a reality for our patients.  City of Hope was founded by individuals’ philanthropic efforts 100 years ago. Their efforts - and those of our supporters today - have built the foundation for the care we provide and the research we conduct. It enables City of Hope to strive for new breakthroughs and better therapies, ultimately helping more people enjoy longer, better lives.

For more information on supporting this specific program, please contact our Philanthropy Department at 800-667-5310 or philanthropy@coh.org. Or, to make a gift that supports all the research at City of Hope, donate online now.

 
We thank you for your support.
 
 
 
Patient Care Overview

City of Hope Locations

Faces of Cancer

Meet City of Hope patients and their families.
 
 
Clinics/Treatments/Services
As a Comprehensive Cancer Center – the highest designation given by the National Cancer Institute – we are widely regarded as a leader in cancer prevention and treatment.

Cancer Expertise Matters


NEWS & UPDATES
  • Upon completing her final round of chemotherapy for ovarian cancer earlier this month, Maria Velazquez-McIntyre, a 51-year-old Antelope Valley resident, celebrated the milestone by giving other patients a symbol of hope – a Survivor Bell. The bell may look ordinary, but for cancer patients undergoing chemothera...
  • Many Americans understand that obesity is tied to heart disease and diabetes but, according to a new survey, too few – only 7 percent – know that obesity increases the risk of cancer. Specific biological characteristics can increase cancer risk in obese people, and multiple studies have shown correlations betwe...
  • As breast cancer survivors know, the disease’s impact lingers in ways both big and small long after treatment has ended. A new study suggests that weight gain – and a possible corresponding increase in heart disease and diabetes risk – may be part of that impact. In the first study to evaluate weight chan...
  • Becoming what’s known as an independent scientific researcher is no small task, especially when working to translate research into meaningful health outcomes. Yet that independent status is vital, enabling researchers to lead studies and avenues of inquiry that they believe to be promising. Clinicians, especial...
  • 720 days. That’s how long Alex Tung, 38, had to give up surfing after being diagnosed with acute myeloid leukemia. For most people, even some surfers, such a hiatus wouldn’t be a big deal, but for Tung, surfing has been everything. The Southern California resident began surfing when he was in elemen...
  • There are few among us who have not experienced loss of a friend or loved one, often without warning, or like those of us who care for people with cancer, after a lingering illness. It is a time when emotions run high and deep, and as time passes from the moment of loss, we often […]
  • For the past four years, neurosurgeon and scientist Rahul Jandial, M.D., Ph.D., has been studying how breast cancer cells spread, or metastasize, to the brain, where they become life-threatening tumors. Known as secondary brain tumors, these cancers have become increasingly common as treatment advances have ena...
  • Cutaneous T cell lymphomas are types of non-Hodgkin lymphoma that arise when infection-fighting white blood cells in the lymphatic system – called lymphocytes – become malignant and affect the skin. A primary symptom is a rash that arises initially in areas of the skin that are not normally exposed to sunlight....
  • There’s science camp, and then there’s “mystery” science camp. City of Hope’s new science camp for middle school students is of the especially engaging latter variety. From Monday, July 13, to Friday, July 17, rising middle-school students from across the San Gabriel Valley were presented with a “patient” with ...
  • Women diagnosed with breast cancer quickly learn their tumor’s type, meaning the characteristics that fuel its growth. That label guides the treatment of their disease, as well as their prognosis when it comes to treatment effectiveness. Sometimes, however, doctors can’t accurately predict treatment effectivene...
  • In years past, Bladder Cancer Awareness Month has been a sobering reminder of a disease with few treatment options. For patients with metastatic disease (disease that has spread from the bladder to distant organs), average survival is typically just over one year. Fortunately, things are changing. Academic inst...
  • Tina Wang was diagnosed with Stage 4 diffuse large b cell lymphoma at age 22. She first sought treatment at her local hospital, undergoing two cycles of treatment. When the treatment failed to eradicate her cancer, she came to City of Hope. Here, Wang underwent an autologous stem cell transplant and participate...
  • When Gilbert Fresquez, 72, lost an excessive amount of weight in late 2012, he didn’t think much of it. He assumed it was a side effect from a recent surgery to remove a carcinoid tumor in his small intestine. It wasn’t until a couple of years later during a routine doctor’s visit that the retired […]
  • Bladder cancer is a disease in which malignant (cancer) cells form in the tissues of the bladder. Among both men and women, the rates of new cancers have decreased in recent years. Death rates, meanwhile, have declined among women and have held stable among men. Specialists at City of Hope are internationally r...
  • The transplant patient had been hospitalized for a couple of months. A professional violinist, he hadn’t touched his instrument for too long, ever since chemotherapy had caused his skin to peel and his fingers to go numb; they were too sensitive even to touch the metal strings, much less make them sing. He had ...